Khademi Bijan, Khademi Behzad, Ghaderi Abbas, Hosseini Seyd Fakhroddin, Niknejad Nika
Department of Otorhinolaryngology, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shira, Iran.
Iran J Otorhinolaryngol. 2013 Jun;25(72):161-8.
The presence of HER-2 has been shown to be a prognostic factor in many kinds of cancers, but its role in head and neck squamous cell carcinoma (HNSCC) is not still defined. The purpose of the current study is to investigate the role of HER-2 in HNSCC and its correlation with various clinicopathologic parameters.
Peripheral blood samples were obtained from 17 healthy volunteers and 69 patients with HNSCC before curative surgery. The HER-2 level was determined in each sample sandwich by ELISA. Statistical analysis was performed using an independent t-test, one-way ANOVA, and the Duncan procedure.
Mean HER-2 serum levels were higher in patients with HNSCC compared with healthy controls, although the difference was not statistically significant (3.85ng/ml vs. 3.75ng/ml; P>0.05). The mean serum level of HER-2 in patients with was higher in patients with lymph node involvement, metastasis, invasion, tumor size ≥2 cm, and stage>1, although the differences were not statistically significant (P>0.05).
Mean HER-2 serum levels in patients with tumor size T3 and higher were higher than those from patients in stage T1 and T2.over expression of these receptor translate into disease progression, growth and invasiveness, with the increase serum HER-2 levels in such patients offering some support for this theory.
In this study the mean HER-2 serum level in patients with HNSCC was found to be greater in comparison with the healthy control group, although the difference was statistically insignificant. From the analysis of the results of the current study we have come to the conclusion that by increasing sample size the rising of the serum HER-2 level in patients with HNSCC can be meaningful. Apart from this, the role of HER-2 as a tumor marker in patients with HNSCC is still controversial and needs further studies to clarify the significance of this biomarker for early detection or screening for HNSCC.
HER-2的存在已被证明是多种癌症的预后因素,但其在头颈部鳞状细胞癌(HNSCC)中的作用尚未明确。本研究旨在探讨HER-2在HNSCC中的作用及其与各种临床病理参数的相关性。
在根治性手术前,从17名健康志愿者和69例HNSCC患者中采集外周血样本。通过ELISA双抗体夹心法测定每个样本中的HER-2水平。采用独立样本t检验、单因素方差分析和Duncan检验进行统计学分析。
HNSCC患者的HER-2血清平均水平高于健康对照组,尽管差异无统计学意义(3.85ng/ml对3.75ng/ml;P>0.05)。有淋巴结转移、远处转移、肿瘤侵犯、肿瘤大小≥2cm以及分期>1期的患者,其HER-2血清平均水平较高,尽管差异无统计学意义(P>0.05)。
肿瘤大小为T3及以上患者的HER-2血清平均水平高于T1和T2期患者。这些受体的过度表达会导致疾病进展、生长和侵袭性,此类患者血清HER-2水平升高为这一理论提供了一定支持。
本研究发现HNSCC患者的HER-2血清平均水平高于健康对照组,尽管差异无统计学意义。通过对本研究结果的分析,我们得出结论,增加样本量后,HNSCC患者血清HER-2水平的升高可能具有意义。除此之外,HER-2作为HNSCC患者肿瘤标志物的作用仍存在争议,需要进一步研究以阐明该生物标志物对HNSCC早期检测或筛查的意义。